Neurostimulation for Pediatric Obstructive Sleep Apnea
Up to 80% of children with Down syndrome (DS) are affected by obstructive sleep apnea (OSA), and only 16% to 30% will have resolution of their OSA with adenotonsillectomy. Hypoglossal nerve stimulation is a well-established therapy for adults with OSA and was recently approved by the Food and Drug Administration for use in children with DS and residual OSA. There is robust experience with this therapy in adults that has led to well-established care pathways. However, given the challenges inherent to caring for a complex pediatric population, these pathways are not directly transferrable to children with DS.
Source: Otolaryngologic clinics of North America - Category: ENT & OMF Authors: Doug Chieffe, Christopher Hartnick Source Type: research
More News: Brain | Children | Down's Syndrome | ENT & OMF | Food and Drug Administration (FDA) | Neurology | Obstructive Sleep Apnea | Pediatrics | Sleep Apnea | Sleep Disorders | Sleep Medicine